News

Dr. Yiumo Michael Chan, VP of Research and Translational Medicine from AnnJi Pharmaceuticals (AnnJi) was invited to speak at 2022 Kennedy’s Disease Association Conference (November 9-11, 2022) held in San Diego, California to introduce the first-in-patient study of AJ201 for the treatment of Kennedy’s Disease, or SBMA. Dr. Chan’s presentation was eagerly anticipated and well […]

2022 Interdisciplinary Neuroscience Congress organized by Taiwan Neuroscience Alliance (TNA) was held in Linkou Chang Gung Medical Foundation, Taiwan, from September 2 to 4. TNA is gathered 16 neuroscience-related societies, ranging from basic to clinical neuroscience, from computational to cognitive neuroscience, and from technology to therapeutic advances. Its Award Committee awarded the AnnJi representative Dr.

AnnJi Pharmaceutical Co., Ltd. is launching the first-in-patient study of AJ201 for the treatment of SBMA (Spinal and Bulbar Muscular Atrophy, or Kennedy’s Disease) to evaluate the safety and clinical responses of AJ201. This study will take place in six clinical sites across the United States and patient recruitment is expected to begin in late

Dr. Cheng-Lung (Andy) Chen presented a scientific poster in “2022 Annual Meeting of Taiwan Neurological Society” titled “A Phase 1, Randomized, Double Blind, Placebo Controlled Study, To Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD-MAD) of AJ201 in Healthy Volunteers”, in which pharmacological safety and pharmacokinetics (PK) of AJ201 in

AnnJi’s scientists published an Opinion in the International Journal of Dermatology and Clinical Research (IJDCR), in which AnnJi presented evidences that J9 and JM17 (the APIs of AJ101 and AJ201, respectively) enhance the degradation of androgen receptors and activate the antioxidant responses. AJ101 is a topical cream formulation being developed for the treatment of acne

To raise awareness of Kennedy’s Disease and to bring resources to support relevant research programs, AnnJi supported the international fundraising activities co-organized by the Kennedy’s Disease Association in the UK and the US, “The Great Road Trip” in early 2022. In the “Great Road Trip”, the donors and volunteers took turns driving a 40-year-old Citroen

AJ201 is a first-in-class pleiotropic small molecule under development by AnnJi for the treatment of Kennedy’s disease, a rare neurological disorder. Patient enrollment of a Phase 2a trial for AJ201 will be initiated in the US by the end of 2022. Dr. Tsung-Pin (Andrew) Pai presented a scientific poster in “2022 International Conference of Big

AnnJi is a clinical-stage pharmaceutical company focusing on developing innovative therapeutics to improve the quality of life of patients with dermatological and neurological diseases. Watch online (below or BIOAsia-Taiwan 2022 if you have registered for the conference), for the latest update of our clinical projects: AJ101 for dermatology and AJ201 for rare neurological diseases. We

AnnJi will be attending BIO Asia–Taiwan 2022, July 27-31, to meet with potential pharmaceutical partners and investors regarding AnnJi’s programs in dermatology and neurology. Dr. K. Karen Lin, the Director of Business Development, is going to present company’s clinical profiles on site at 16:15, July 27 (https://bioasiataiwan.com/en/program/detail/46). AnnJi welcome an opportunity to meet with you

On 14th, May 2022, Taiwania Capital and Development Center for Biotechnology (DCB) invited Dr. Wendy Huang, Chair and CEO of AnnJi Pharmaceutical (AnnJi), to give a lecture on “New Opportunities for Small Molecule Drug Development”. Dr. Wendy Huang gave an overview about the recent AI technologies in aiding new drug design, the novel drug delivery